BCKDK and ovarian serous adenocarcinoma: To confirm the results of our screen that identified BCKDK as a potential determinant of the sensitivity of ovarian cancer cells to paclitaxel [3], we first assessed the expression of BCKDK and BCKDH in eight ovarian cancer cell lines including those that have been shown to be among those most representative of high-grade serous ovarian cancer [33].